•Advancing Equity and Patient Partnership in Clinical Trials for Inflammatory Bowel Disease: A Model for Inclusive Trial Design
•Shaping the research agenda of pediatric gastroenterology, hepatology, and nutrition: The proposal from a SIGENP expert groups
•Reprogramming the gastrointestinal microenvironment with intelligent biomaterials and digital medicine: a perspective on precision intervention for digestive diseases
•CAR-T cells and CAR-Treg cells for treatment of inflammatory bowel diseases
•A case series study of fever-diarrhea-hematochezia triad as the first presentation in plasma EBV DNA-positive diseases
